

ASSIGNMENT

THIS ASSIGNMENT is by and between Eluminex Biosciences (Suzhou) Limited (典晶生物医药科技（苏州）有限公司 in Chinese) having an address at B7-401, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China (a/k/a, 4th Floor, Building B7, Suzhou Industrial Park, 218 Xinghu Street, Suzhou, China 215123; or 4th Floor, Building 7, Xinghu Street, Suzhou Industrial Park, BioBAY, Suzhou, Jiangsu 215123, China; or 4th Floor, Building B7, 218 Xinghu Street, Suzhou Industrial Park BioBAY Suzhou, Jiangsu 215000, China. “Assignor”) and Eluminex Biosciences Limited having an address at Aequitas International Management Ltd., Grand Pavilion Commercial Centre, Suite 24, 802 West Bay Road, P.O. Box 10281, Grand Cayman KY1-1003, Cayman Islands (“Assignee”).

Assignor warrants that it is the owner of the one or more inventions (the “Inventions”) described in the applications (“Applications”) listed in the Appendix 1 attached to this assignment.

Assignee desires to acquire the entire right, title and interest in and to the Inventions and the Applications, and in and to any patents (collectively, “Patents”) that may be granted for the Inventions and Applications in any and all countries and regions in the world.


For valuable consideration, the receipt and sufficiency of which Assignor acknowledges, Assignor hereby sells, assigns, and transfers to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to: the Inventions, the Applications, and any Patents; any divisions, continuations, continuations-in-part, non-provisional, international applications, and national phase applications of the Applications, any other applications claiming priority rights from the Applications; any other applications applied for the Inventions; any reissues, reexaminations, renewal or extensions of any and all Patents; the right to file patent applications directly in the name of Assignee (in countries where such filings are permissible); and the right to claim priority rights deriving from the Applications; and the right to recover and take all such proceedings as may be necessary for the recovery of damages or otherwise in respect of all past, present or future acts of infringement or alleged infringement of the rights assigned and transferred by this Agreement (collectively, the “Rights”), whether now existing or hereafter arising.

Assignor warrants that the Rights are unencumbered. Assignor agrees to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as Assignee deems necessary or desirable to: perfect Assignee’s enjoyment of the Rights; prepare, file, prosecute and maintain the Applications or any other applications for Patents; conduct proceedings regarding the Rights, including any reissues, reexaminations, inter partes review, opposition and any other post-grant proceedings, cancellation proceedings, public use proceedings, litigation, interference, invalidation or derivation proceedings; perfect or defend title to the Rights; or enable the Assignee to enjoy to the fullest extent the Rights in any and all countries and regions in the world, or under any international convention, agreement, protocol, or treaty. Assignor requests the Commissioner of Patents or any other office of similar authority to issue any Patents that may be issued on the Inventions to Assignee.

[Signature Pages Follow]

Confidential

ASSIGNOR: Eluminex Biosciences (Suzhou) Limited (典晶生物医药科技(苏州)有限公司 in Chinese)



By:

Signature

(Seal)

Date

Feb. 19, 2025

Print Name

Title

Jinzhong Zhang

CEO

ASSIGNEE: Eluminex Biosciences Limited

By:

Signature

Date

Feb. 19, 2025

Print Name

Title

Jinzhong Zhang

CEO

Appendix 1 - List of Applications

No.	Title	Matter Type	Country or Region	Status	Application #	Date Filed
1	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Australia	Pending	2021372759	10/26/2021
2	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Canada	Pending	3200307	10/26/2021
3	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	China	Pending	202180073928.0	10/26/2021
4	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	European Patent Office	Pending	21885167.3	10/26/2021
5	INHIBITORS OF ANGIOGENIC FACTORS	Utility - CONF	Hong Kong	Pending	62024086390.7	10/26/2021
6	INHIBITORS OF ANGIOGENIC FACTORS	Utility - CONF	Hong Kong	Pending	62024086391.5	10/26/2021
7	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Japan	Pending	2023-550344	10/26/2021
8	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Republic of Korea	Pending	10-2023-7018045	10/26/2021
9	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Mexico	Pending	MX/a/2023/004839	10/26/2021
10	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	Russian Federation	Pending	2023110659	10/26/2021
11	INHIBITORS OF ANGIOGENIC FACTORS	Utility - NSPCT	United States of America	Pending	18/250,977	10/26/2021
12	INHIBITORS OF ANGIOGENIC FACTORS	Utility - ORG	WIPO	Expired	PCT/CN2021/126470	10/26/2021
13	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Australia	Pending	2022227047	02/17/2022
14	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Canada	Pending	3211803	02/17/2022
15	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	China	Pending	202280017398.2	02/17/2022

16	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	European Patent Office	Pending	22758797.9	02/17/2022
17	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - CONF	Hong Kong	Pending	62024089893.7	02/17/2022
18	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - CONF	Hong Kong	Pending	62024093092.0	02/17/2022
19	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Japan	Pending	2023-551991	02/17/2022
20	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Republic of Korea	Pending	10-2023-7033126	02/17/2022
21	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Mexico	Pending	MX/a/2023/009956	02/17/2022
22	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	Russian Federation	Pending	2023120383	02/17/2022
23	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - ORG	Taiwan	Pending	111106352	02/22/2022
24	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - NSPCT	United States of America	Pending	18/548,104	02/17/2022
25	ANTIBODY FUSION PROTEINS TARGETING IL-6 RECEPTOR AND ANGIOGENIC FACTORS	Utility - ORG	WIPO	Expired	PCT/CN2022/076673	02/17/2022
26	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC AND	Utility - ORG	Taiwan	Pending	113131368	08/21/2024

	INFLAMMATORY FACTORS					
27	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC AND INFLAMMATORY FACTORS	Utility - ORG	WIPO	Pending	PCT/CN2023/11 8036	09/11/2023
28	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC, INFLAMMATORY, AND/OR FIBROTIC FACTORS	Utility - ORG	Taiwan	Pending	113144089	11/15/2024
29	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC, INFLAMMATORY, AND/OR FIBROTIC FACTORS	Utility - ORG	WIPO	Pending	PCT/CN2023/13 4829	11/28/2023
30	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC FACTORS	Utility - ORG	WIPO	Pending	PCT/CN2024/11 1878	08/13/2024
31	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC AND INFLAMMATORY FACTORS	Utility – Provisional	United States of America	Pending	63/732,478	08/19/2024
32	MULTISPECIFIC FUSION PROTEINS TARGETING ANGIOGENIC AND INFLAMMATORY FACTORS	Utility - Provisional	United States of America	Pending	63/833,332	11/15/2024